中国合理用药探索2025，Vol.22Issue(2)：23-29,7.DOI:10.3969/j.issn.2096-3327.2025.02.004
加拿大《2023 BC指南:直接口服抗凝药物》解读
Interpretation of 2023 BC Guidelines:Direct Oral Anticoagulants
摘要
Abstract
In order to guide the rational use of direct oral anticoagulants(DOACs),2023 BC Guidelines:Direct Oral Anticoagulants(referred to as BC guidelines)by Canada provide recommendations for the use of DOACs in adults aged≥19 years for the following indications,including:prevention of stroke and systemic embolism in non-valvular atrial fibrillation(NVAF);treatment of venous thromboembolism(VTE)with stable hemodynamics;prevention of arterial vascular events in patients with stable coronary artery disease(CAD),with or without peripheral arterial disease(PAD).This article provides an interpretation of the BC guidelines and compares them with the Pharmaceutical Recommendation on Rational Use and Prescription Quality Evaluation of Direct Oral Anticoagulants issued in China in 2024,aiming to guide the rational use of DOACs.关键词
直接口服抗凝药物/指南解读/合理用药/处方质量/用药安全Key words
direct oral anticoagulants/interpretation of guidelines/rational use/prescription quality/drug safety分类
药学引用本文复制引用
景智,丁征..加拿大《2023 BC指南:直接口服抗凝药物》解读[J].中国合理用药探索,2025,22(2):23-29,7.基金项目
阜院基金(T2023-ZX037):直接口服抗凝药物临床综合评价 （T2023-ZX037）
